Marine Guidance Note

MGN 296

Medication at sea

In force
In force
Version
As first issued
Published
28 October 2005
Applies to
Merchant ships · Large commercial yachts · Small commercial vessels
Topics
Medical · MLC and crew welfare

xplor’s summary, not the official text

This guidance note alerts ship owners, operators, managers, manning agencies, masters and seafarers to the potential effects of prescription and over-the-counter medication on performance at sea. It asks seafarers to disclose medication likely to affect their ability to work safely, and recommends employers develop management systems to minimise risks while respecting confidentiality. It sets out risk management options ranging from high protection with pre-departure clearance to no special measures, and includes an indicative list of medications with potential performance effects and a sample carry card. It is published October 2005.

Written by xplor from the notice's text on 17 November 2026. It is a summary, not the notice: rely on the official text.

For yacht crew

Seafarers working on commercially operated yachts should disclose to their employer any medication that might affect their ability to carry out safety-critical duties safely.

Sections of the notice

  1. 1. Background
  2. 2. The risks of medication use at sea
  3. 3. Risk Management Principles
  4. 4. Responsibilities for Risk Reduction
  5. 5. Risk Management Options
  6. 6. Recommended actions
  7. 7. Sources of Help
  8. 8. Any prescription medication which needs to be held in reserve and used in the case of
  9. Appendix 2

The notice's own headings. The text of each is in the official notice on GOV.UK.